Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Stifel Upgrades eFFECTOR Therapeutics to Buy, Announces $20 Price Target

Stifel analyst Benjamin Burnett upgrades eFFECTOR Therapeutics (NASDAQ:EFTR) from Hold to Buy and announces $20 price target.
byBenzinga Newsdesk
November 9, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

Stifel analyst Benjamin Burnett upgrades eFFECTOR Therapeutics (NASDAQ:EFTR) from Hold to Buy and announces $20 price target.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts